I had invested a small amount here at 3 hoping to triple it in a year to 9+ and then sell it out to sponsor a child's facial reconstruction surgery (in another continent). Obviously, the original charity funds were not sufficient to cover the entire cost and the surgery was not urgent; hence thought that, let the funds grow here first, for a year, and then I should be able to take care of the entire cost. But, given the selloff today, looks like those plans got postponed now. Any one here has any thoughts as to when will it reach the $3 level again and any other small biotech stock, they can suggest, which might triple in a year? Obviously, once invested (in that account), I won't be able to track it regularly for a year. So, need some peaceful type growth stock for the charity funds. I would really like to sponsor the surgery of a child some day! Thanks for any input in advance. May the Lord bless you all!
From 3 to 7 it went up; I was just 2 bucks short of the target and cashing out for the surgery! Feel so sad also for the kid, who had his hopes indirectly riding on this. The eyes are also drying out now ... no moisture left to shed! Any other good idea jbarba_us? Thanks in advance.
Go follow Baker Brothers (biotech) and invest when they do. Even with public docs, you'll still do better than investing in ZLCS, where they reverse stock split 6:1 just a while ago to avoid delisting... and will likely do so again. Meantime, the CxO levels get $600K, 400K, 400K base salary still. They are the winners in all of this, not investors.
Sentiment: Strong Sell
I have a large portion of my speculative portfolio in ACRX and VTUS. Please, do your own DD on these. In my opinion they are pretty solid. ACRX should pop in 2014 - it has several promising drugs in the pipeline, and the management team is stellar. VTUS has a medication specific to a particular medical issue not currently addressed by other medications (anal fissures). I would also consider the 3-D copier sector (DDD, SSYS, and XONE). But do your homework. Good luck.